Considerations for Parenteral Dosage Form Development of Natural Alpha Interferon

Sean Evans and Peter Grassam


Parenteral dosage form development of novel pharmaceuticals with natural or recombinant proteins present specific challenges in order to obtain a stable, manufacturable, and marketable product. An understanding of the physical and chemical properties of the bulk active is essential for the efficient development of stable and efficacious dosage forms. Several parameters that must be considered and evaluated for such a development, are listed: (1) Screening and selection of compatible excipients, (2) container and closure selection, (3) method of sterilization (4) factors such as thermal and mechanical stress, and (5) other parameters will be reviewed.

  • Received April 6, 1986.
  • Accepted April 30, 1986.

PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.  

If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing. 

Full issue PDFs are for PDA members only.

Note to users

The PDA and PDA bookstore websites ( and are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.

Log in through your institution

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.